New York State Common Retirement Fund
TRVI icon

New York State Common Retirement Fund’s Trevi Therapeutics TRVI Stock Holding History

New York State Common Retirement Fund’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$702K Buy
37,665
+9,900
+36% +$144K ﹤0.01% 1874
2026
Q1 		$331K Hold
27,765
– – ﹤0.01% 2053
2025
Q4 		$348K Hold
27,765
– – ﹤0.01% 2092
2025
Q3 		$254K Buy
27,765
+12,500
+82% +$93.7K ﹤0.01% 2189
2025
Q2 		$83.5K Hold
15,265
– – ﹤0.01% 2780
2025
Q1 		$96K Hold
15,265
– – ﹤0.01% 2536
2024
Q4 		$62.9K Hold
15,265
– – ﹤0.01% 2784
2024
Q3 		$51K Hold
15,265
– – ﹤0.01% 2862
2024
Q2 		$45.5K Buy
15,265
+207
+1% +$575 ﹤0.01% 3109
2024
Q1 		$52K Sell
15,058
-21,644
-59% -$48.3K ﹤0.01% 2971
2023
Q4 		$49.2K Sell
36,702
-83
-0.2% -$126 ﹤0.01% 3001
2023
Q3 		$80.2K Buy
36,785
+485
+1% +$1.1K ﹤0.01% 2831
2023
Q2 		$86.8K Buy
+36,300
New +$91.5K ﹤0.01% 2963

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

New York State Common Retirement Fund's TRVI Position: Q2 2026 in Review

New York State Common Retirement Fund increased its Trevi Therapeutics (TRVI) stake by 36% in Q2 2026, buying an estimated $144K and bringing the position to 37,665 shares worth $702K. The position accounts for ﹤0.01% of the portfolio, ranked #1874.

New York State Common Retirement Fund first reported a position in TRVI in Q2 2023 and has held it in 13 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • New York State Common Retirement Fund held 37,665 shares of Trevi Therapeutics worth $702K as of Q2 2026.
  • New York State Common Retirement Fund bought 9,900 Trevi Therapeutics shares in Q2 2026, an estimated $144K.
  • Trevi Therapeutics made up ﹤0.01% of New York State Common Retirement Fund's portfolio in Q2 2026, its #1874 holding.
  • New York State Common Retirement Fund first reported a position in Trevi Therapeutics in Q2 2023 and has held it in 13 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.